吉斯基任命卢克·米尔斯为首席执行官,自2026年1月1日起,继任艾玛·沃尔姆斯利. GSK names Luke Miels CEO, effective Jan. 1, 2026, succeeding Emma Walmsley.

GGSK将卢克·米尔斯命名为下一任首席执行官,从2026年1月1日开始,接替艾玛·沃尔姆斯利,他将在九年后下台。 GSK has named Luke Miels as its next CEO, effective January 1, 2026, succeeding Emma Walmsley, who will step down after nine years. 米尔斯(Miels)目前为首席商业官, 将带领该公司在2031年前推动超过400亿英镑的销售。 Miels, currently chief commercial officer, will lead the company’s push to exceed £40 billion in sales by 2031. 董事会根据他的全球生物制药经验和对GSK的深入了解,按照严格的程序挑选了他。 The board selected him following a rigorous process, citing his global biopharma experience and deep knowledge of GSK. 沃尔姆斯利 （Walmsley） 带领公司完成了包括 Haleon 分拆在内的重大转型，他将留任至 2026 年 9 月。 Walmsley, who guided the company through a major transformation including the Haleon spin-off, will remain until September 2026. 被描述为出乎意料的领导层变化将GSK股份提高了3.5%。 The leadership change, described as unexpected, boosted GSK shares by 3.5%.